Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- TH +12.4%, NESR +11.4%, CECO +11.4%, IMOS +7.6% (July revs), SDRL +7.5%, CAMT +6.9%, EMBJ +5%, RDNT +4.8%, ASX +4.7% (July revs), KEEL +3.3%, KSPI +2.6%, CTRN +1.9%, FERG +1.3%, INSW +1.2%,
Other news:
- VREX +48.7% (Teledyne to acquire Varex Imaging (VREX) for $18.90/share in cash)
- ABCL +30.2% (reports Top-Line Phase 2 clinical trial results for ABCL635)
- IPHA +22% (says Sobi (SOBI) partnership supports lacutamab Phase 3 plan; names Markus Jensen CMO; partners with Sobi (SOBI) on lacutamab in T-cell lymphoma)
- SLN +8.5% (to host conference call and webcast to discuss topline results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera)
- OCS +3.9% (to acquire worldwide Privosegtor rights from Accure Therapeutics)
- WCN +2% (renews NCIB for up to 12.58M shares)
- CBLL +2% (gets FDA 510(k) clearance for two AI enhancements in Neurology Portal)
- AQST +1.5% (reports Anaphylm human factors, PK data ahead of planned Q3 NDA resubmission)
- RNW +1.3% (agreed to sell 1,055 MW of its solar projects in Rajasthan and Karnataka to Purvah Green Power Private Limited)
- RCAT +1% (announces multiyear partnership with Washington Commanders)
- TDY +1% (Teledyne to acquire Varex Imaging (VREX) for $18.90/share in cash)